EVMN logo
NYSE · EVMNBiotechnologyUpdated Nov 2, 2026

Evommune, Inc. ROE

Profitability, historical returns, and peer comparisons.

The ROE as of November 2026 (TTM) for Evommune, Inc. (EVMN) is -62.63%

According to Evommune, Inc.’s latest financial reports and current stock price. The company's current ROE is -62.63%. This represents a change of 875.81% compared to the average of -6.42% of the last 4 quarters.

Evommune, Inc. (EVMN) Historical ROE (quarterly & annually)

How has EVMN ROE performed in the past?

The mean historical ROE of Evommune, Inc. over the last ten years is 18.88%. The current -62.63% ROE has changed -431.79% with respect to the historical average. Over the past ten years (40 quarters), EVMN's ROE was at its highest in in the March 2025 quarter at 9.20%. The ROE was at its lowest in in the December 2024 quarter at -38.54%.

Quarterly (TTM)
Annual

Average

18.88%

Median

43.82%

Minimum

-33.50%

Maximum

46.32%

Evommune, Inc. (EVMN) ROE by Quarter and Year

Discovering the peaks and valleys of Evommune, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 5.71%

Maximum Annual ROE = 46.32%

Minimum Annual Increase = -172.33%

Minimum Annual ROE = -33.50%

Quarterly (TTM)
Annual
YearROEChange
2025-33.50%-172.33%
202446.32%5.71%

Evommune, Inc. (EVMN) Average ROE

How has EVMN ROE performed in the past?

The current ROE of Evommune, Inc. (EVMN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

18.88%

5-year avg

18.88%

10-year avg

18.88%

Evommune, Inc. (EVMN) ROE vs. Peers

How is EVMN’s ROE compared to its peers?

Evommune, Inc.’s ROE is greater than Artiva Biotherapeutics, Inc. (-53.86%), greater than Codexis, Inc. (-74.36%), greater than Climb Bio, Inc. (-31.79%), greater than EyePoint Pharmaceuticals, Inc. (-135.81%), greater than Fortrea Holdings Inc. (-12.81%), less than Galapagos N.V. (16.88%), less than Karyopharm Therapeutics Inc. (77.63%), less than Ligand Pharmaceuticals Incorporated (5.22%), greater than OmniAb, Inc. (-16.73%), greater than Zymeworks Inc. (-72.07%),

Build a custom stock screener for Evommune, Inc. (EVMN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evommune, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Evommune, Inc. (EVMN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Evommune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Evommune, Inc.'s ROE?

How is the ROE calculated for Evommune, Inc. (EVMN)?

What is the highest ROE for Evommune, Inc. (EVMN)?

What is the 3-year average ROE for Evommune, Inc. (EVMN)?

What is the 5-year average ROE for Evommune, Inc. (EVMN)?

How does the current ROE for Evommune, Inc. (EVMN) compare to its historical average?